Capital One analyst Zegbeh Jallah remains bullish on Arvinas following the company’s Q4 corporate update. The company reported $1.2B in cash and equivalents and highlighted "impressive progress" and upcoming catalysts for its Phase 3 programs, as well plans for pipeline expansion, the analyst tells investors in a research note. The firm says Arvinas is still one of the best biotech stocks to own. It keeps an Overweight rating on the shares with an $88 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARVN:
- Arvinas expects cash to fund requirements into 2026
- Arvinas reports Q4 EPS ($1.56), consensus ($1.22)
- Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- Arvinas to Participate in Upcoming Investor Conferences
- Cantor biotech/biopharma analysts hold analyst/industry conference call
